艾地骨化醇联合利塞膦酸减少绝经后乳腺癌患者芳香化酶抑制剂所致骨丢失
该开放标签随机对照试验纳入接受芳香化酶抑制剂治疗的激素受体阳性早期乳腺癌绝经后女性,比较艾地骨化醇(0.75 μg/日)联合利塞膦酸(17.5 mg/周)与利塞膦酸单药治疗24个月对骨密度和骨质量的影响。联合治疗组腰椎骨密度增加较单药组更大,组间差异为0.020 g/cm2(95%CI:0.010-0.029 g/cm2,P<.001);形态学椎体骨折发生率比值为0.292(95%CI:0.080-1.061,P=.061);骨小梁评分变化未检测到组间差异。
要点
- 艾地骨化醇联合利塞膦酸较单药增加腰椎骨密度,组间差异0.020 g/cm2(95%CI:0.010-0.029,P<.001)。
- 形态学椎体骨折发生率比值0.292(95%CI:0.080-1.061,P=.061)。
- 骨小梁评分变化未检测到组间差异。
核心结论
- 在骨量减少至骨质疏松的绝经后女性中,艾地骨化醇联合利塞膦酸治疗增加了接受芳香化酶抑制剂和利塞膦酸治疗患者的腰椎骨密度。
研究设计与样本
- 开放标签随机对照试验。
- 纳入200例激素受体阳性早期乳腺癌(TNM分期0-3A)绝经后女性,接受利塞膦酸治疗超过12个月。
- 排除无随访骨密度数据者后,196例纳入全分析集。
- 参与者被建议补充维生素D和钙,但许多存在维生素D缺乏或不足。
- 按1:1比例随机分配至艾地骨化醇(0.75 μg/日)联合利塞膦酸(17.5 mg/周)组或利塞膦酸单药组。
主要发现
- 24个月时腰椎、股骨颈和全髋骨密度增加在联合治疗组大于单药组,腰椎骨密度组间差异(联合治疗减单药)估计为0.020 g/cm2(95%CI:0.010-0.029 g/cm2,P<.001)。
- 形态学椎体骨折发生率比值(联合治疗/单药)为0.292(95%CI:0.080-1.061,P=.061)。
- 骨小梁评分变化未检测到组间差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR + EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis. OBJECTIVE: To determine the effect of eldecalcitol (0.75 ug/day) add-on therapy to risedronate (17.5 mg/week) on bone quantity and quality in women treated with AI. DESIGN: Open-label randomized control trial. SETTING: Postmenopausal women with HR + EBC (TNM stage 0-3A) treated with risedronate for more than 12 months. PATIENTS: Two hundred patients were enrolled; 196 patients were eligible for the full analysis set after excluding those without follow-up BMD data. Participants were advised to take vitamin D and calcium, yet many were vitamin D deficient or insufficient. INTERVENTION: Participants were randomly assigned in a 1:1 ratio to receive either eldecalcitol add-on therapy or risedronate monotherapy. MAIN OUTCOME MEASURE: The primary outcome was the group difference in the change of lumbar spine (LS)-BMD in 24 months. Secondary outcomes included femoral neck (FN)-BMD, total hip (TH)-BMD, trabecular bone score (TBS), and the incidence of vertebral and nonvertebral fractures. RESULTS: The increase at LS-, FN-, and TH-BMD at 24 months was larger in the add-on therapy group than in the monotherapy group, with a group difference (add-on therapy minus monotherapy) estimate of 0.020 g/cm2 [95% confidence interval (CI): 0.010-0.029 g/cm2, P < .001] for LS-BMD. The incidence rate ratio (add-on therapy/monotherapy) for morphometric vertebral fractures was 0.292 (95% CI: 0.080-1.061, P = .061). No group difference was detected in the change in TBS. CONCLUSION: Eldecalcitol add-on therapy increased LS-BMD in osteopenic to osteoporotic postmenopausal women treated with an AI and risedronate.
引用
- Imanishi Y, Imai T, Fujii H, et al. Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. J Clin Endocrinol Metab. 2025. PMID: 39812183. doi:10.1210/clinem/dgaf019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。